Pfanstiehl Announces New Histidine Products for Biopharmaceutical Formulations
Suitable for bioprocessing, solubilization, and stabilization applications, the new histidine products allow for the control of endotoxin and trace metal impurities reflected with elemental impurity data in parts per billion on their specifications.
Pfanstiehl announced that it has launched high purity, low endotoxin, low metal L-histidine and L-histidine hydrochloride monohydrate for a new quality standard for amino acids.
Suitable for bioprocessing, solubilization, and stabilization applications, the new histidine products allow for the control of endotoxin and trace metal impurities reflected with elemental impurity data in parts per billion on their specifications, a June 25, 2020 company press release said. The products are now available for customer qualification and manufacturing, product profiles, and regulatory documentation.
“Pfanstiehl’s amino acid specifications exceed regulatory requirements and reflect our leadership in setting high quality industry standards for the biopharma market,” said Chandra Kelley, director of business development, Pfanstiehl, in the press release.
Source: Pfanstiehl
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
